Board changes at Addex
This article was originally published in Scrip
Addex Pharmaceuticals has appointed Vincent Lawton vice-chairman of the board. Mr Lawton, previously managing director of Merck Sharp & Dohme, has served on the Addex board since April 2009. In addition, Vincent Mutel has formally resigned his position as an Addex board member, after stepping down as CEO of the company in June 2011.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.